Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Total Non-Current Liabilities: 2022-2025

Historic Total Non-Current Liabilities for Centessa Pharmaceuticals (CNTA) over the last 3 years, with Sep 2025 value amounting to $146.7 million.

  • Centessa Pharmaceuticals' Total Non-Current Liabilities rose 32.70% to $146.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $146.7 million, marking a year-over-year increase of 32.70%. This contributed to the annual value of $175.2 million for FY2024, which is 41.34% up from last year.
  • Latest data reveals that Centessa Pharmaceuticals reported Total Non-Current Liabilities of $146.7 million as of Q3 2025, which was down 0.33% from $147.2 million recorded in Q2 2025.
  • Over the past 5 years, Centessa Pharmaceuticals' Total Non-Current Liabilities peaked at $175.2 million during Q4 2024, and registered a low of $101.0 million during Q2 2022.
  • For the 3-year period, Centessa Pharmaceuticals' Total Non-Current Liabilities averaged around $133.8 million, with its median value being $132.8 million (2023).
  • Data for Centessa Pharmaceuticals' Total Non-Current Liabilities shows a peak YoY soared of 41.34% (in 2024) over the last 5 years.
  • Over the past 4 years, Centessa Pharmaceuticals' Total Non-Current Liabilities (Quarterly) stood at $106.4 million in 2022, then reached $124.0 million in 2023, then skyrocketed by 41.34% to $175.2 million in 2024, then skyrocketed by 32.70% to $146.7 million in 2025.
  • Its Total Non-Current Liabilities stands at $146.7 million for Q3 2025, versus $147.2 million for Q2 2025 and $141.6 million for Q1 2025.